MapLight Therapeutics Q3 2026 Results: Net Loss of $51.6M, Loss Widens
MapLight Therapeutics reported a significant increase in net loss to $172.5 million for the nine months ended September 30, 2026, compared to $81.6 million in the prior year, primarily driven by a doubling of research and development expenses. The company strengthened its balance sheet through a private placement in the third quarter of 2026, yielding $140.1 million in net proceeds.
- Key figure
- Net loss $51.6M